当前位置： SCI文献检索 > BMC CANCER期刊下所有文献 > Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.

Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.

Abstract：

BACKGROUND:Apatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2(VEGFR-2). This study was conducted to assess the efficacy and safety of apatinib in patients with non-triple-negative metastatic breast cancer who had received prior chemotherapy for their metastatic disease. METHODS:This multicenter, open-label, single arm study enrolled patients with non-triple-negative breast cancer, pretreated with anthracycline, taxanes and capecitabine, and who failed in the metastatic setting at least 1 and at most 4 prior chemotherapy regimens and at least one endocrine drug for hormone receptor-positive patients as well as at least one anti-Her2 drug for Her2-positive patients. The primary end point of this study was progression free survival (PFS). Secondary end points included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and toxicity. Apatinib was administered as 500 mg daily on days 1 through 28 of each 4-week cycle. RESULTS:38 patients were enrolled with a median age of 49 years (range, 35 to 62 years) and received apatinib for a median of 4 cycles (range from 0 to 10 cycles). 18 (47.4%) patients experienced dose reduction during treatment. The median relative dose intensity (relative to assigned dose for each cycle) was 82% (range, 45.0% to 100.0%). Median follow-up time was 10.1 months. Median PFS of all 38 patients was 4.0 months (95% confidence interval (CI), 2.8 m - 5.2 m). 36 patients were eligible for efficacy analysis. ORR was 16.7% (6/36). DCR was 66.7% (24/36). Median OS was 10.3 months (95% CI, 9.1 m - 11.6 m). The most common grade 3/4 treatment-related AEs were hypertension (20.5%), hand-foot syndrome (10.3%), and proteinuria (5.1%). Of three possibly drug-related SAEs recorded in the study, 2 (3.4%) deaths occurred within 28 days of last treatment and were both considered to be the result of disease progression. The other one was grade 2 diarrhea needing hospitalization. CONCLUSIONS:Apatinib exhibited objective efficacy in heavily pretreated, metastatic non-triple-negative breast cancer with manageable toxicity, and it might be better to be tested in breast cancer with high angiogenesis dependency. TRIAL REGISTRATION:ClinicalTrials.gov: NCT01653561.

journal_name

BMC Cancer

journal_title

BMC cancer

authors

Hu X,Cao J,Hu W,Wu C,Pan Y,Cai L,Tong Z,Wang S,Li J,Wang Z,Wang B,Chen X,Yu H

doi

10.1186/1471-2407-14-820

subject

Has Abstract

pub_date

2014-11-07 00:00:00

pages

820

issn

1471-2407

pii

1471-2407-14-820

journal_volume

pub_type

杂志文章,多中心研究

在线工具

Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.